NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price, Forecast & News

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) posted its earnings results on Thursday, February, 13th. The biopharmaceutical company reported ($1.62) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.61) by $0.01. The biopharmaceutical company had revenue of $35.59 million for the quarter, compared to analysts' expectations of $32.31 million. Ultragenyx Pharmaceutical had a negative net margin of 388.30% and a negative return on equity of 49.81%. View Ultragenyx Pharmaceutical's Earnings History.

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical updated its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $102-104 million, compared to the consensus revenue estimate of $100.68 million.

11 equities research analysts have issued 1-year target prices for Ultragenyx Pharmaceutical's stock. Their forecasts range from $59.00 to $87.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $75.09 in the next twelve months. This suggests a possible upside of 22.8% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical.

Headlines about RARE stock have trended somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ultragenyx Pharmaceutical earned a news impact score of 1.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Ultragenyx Pharmaceutical.

Some companies that are related to Ultragenyx Pharmaceutical include Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA) and The Medicines (MDCO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Exelixis (EXEL), Gilead Sciences (GILD), Portola Pharmaceuticals (PTLA), TG Therapeutics (TGTX), GALAPAGOS NV/S (GLPG), Netflix (NFLX), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT), Sangamo Therapeutics (SGMO) and Palo Alto Networks (PANW).

Ultragenyx Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (3.81%), FMR LLC (3.16%), First Trust Advisors LP (2.06%), Franklin Resources Inc. (0.64%), Charles Schwab Investment Management Inc. (0.58%) and Bank of New York Mellon Corp (0.40%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Group AG, Rafferty Asset Management LLC, Candriam Luxembourg S.C.A., Cubist Systematic Strategies LLC, Laurion Capital Management LP, New York State Common Retirement Fund and SG Americas Securities LLC. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Shalini Sharp and Theodore Alan Huizenga. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

RARE stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., First Trust Advisors LP, Pinnacle Associates Ltd., State Street Corp, Barclays PLC, Point72 Asset Management L.P., Rothschild & Co. Asset Management US Inc. and Ikarian Capital LLC. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RARE stock can currently be purchased for approximately $61.13.

Ultragenyx Pharmaceutical has a market capitalization of $3.53 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis. View Additional Information About Ultragenyx Pharmaceutical.

The official website for Ultragenyx Pharmaceutical is http://www.ultragenyx.com/.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]